Abbott enrolls first patient in spinal cord stimulation study ... | 合法醫療器材資訊網

2020年10月1日—Abbott(NYSE:ABT)announcedthatitenrolledthefirstpatientinitsDistinctstudytoinvestigateitsBurstDRspinalcordstimulation(SCS).

Abbott[1] (NYSE:ABT[2]) announced that it enrolled the first patient in its Distinct study to investigate its BurstDR spinal cord stimulation (SCS).

The Distinct (dorsal spinal cord stimulation vs. medical management for treatment of low back pain) study seeks to investigate the efficacy of BurstDR SCS compared with conventional medical management (CMM) in people with chronic low back pain that is unmanageable through standard medical care, according to a news release.

Distinct is a prospective, multi-center, randomized, controlled clinical study comparing the SCS system to medication and other non-surgical methods by evaluating improvements in pain, physical function and emotional well-being in the patients who have not had lumbar surgery or for whom surgery is not an option.

Primary and secondary endpoints focus on improvements in physic...